Title: A phase I study of BMS-690514 in Japanese patients with advanced or metastatic solid tumors.
Journal: Cancer chemotherapy and pharmacology 20121001
Title: In vitro characterization of the metabolic pathways and cytochrome P450 inhibition and induction potential of BMS-690514, an ErbB/vascular endothelial growth factor receptor inhibitor.
Journal: Drug metabolism and disposition: the biological fate of chemicals 20110901
Title: Mechanistic studies on a P450-mediated rearrangement of BMS-690514: conversion of a pyrrolotriazine to a hydroxypyridotriazine.
Journal: Chemical research in toxicology 20110114
Title: Metabolism and disposition of [14C]BMS-690514, an ErbB/vascular endothelial growth factor receptor inhibitor, after oral administration to humans.
Journal: Drug metabolism and disposition: the biological fate of chemicals 20101101
Title: Preclinical pharmacokinetics and in vitro metabolism of BMS-690514, a potent inhibitor of EGFR and VEGFR2.
Journal: Journal of pharmaceutical sciences 20100801
Title: BMS-690514, a VEGFR and EGFR tyrosine kinase inhibitor, shows anti-tumoural activity on non-small-cell lung cancer xenografts and induces sequence-dependent synergistic effect with radiation.
Journal: British journal of cancer 20100727
Title: Metabolism and disposition of [14C]BMS-690514 after oral administration to rats, rabbits, and dogs.
Journal: Drug metabolism and disposition: the biological fate of chemicals 20100701
Title: A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib.
Journal: Cancer research 20070701
Title: Wong TW, et al. Antitumor and antiangiogenic activities of BMS-690514, an inhibitor of human EGF and VEGF receptor kinase families. Clin Cancer Res. 2011 Jun 15;17(12):4031-41.
Title: Marathe P, et al. Preclinical pharmacokinetics and in vitro metabolism of BMS-690514, a potent inhibitor of EGFR and VEGFR2. J Pharm Sci. 2010 Aug;99(8):3579-93.
